Journal
BIOMEDICINES
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10020304
Keywords
mdx; DMD; muscular regeneration; hepatocyte growth factor; leukemia inhibitory factor
Categories
Funding
- Lundbeck Foundation [R140-2013-13370]
- Novo Nordisk Foundation [8091]
- AP Moller Foundations [13-222]
- Instituto de Salud Carlos III y Fondos FEDER (FIS Project) [PI19/01313]
- Augustinus Foundation [13-4153]
Ask authors/readers for more resources
This study found that the growth factor cocktail did not significantly improve the functional level of mdx model during treatment, despite positive effects on some muscle types at a molecular level. Additionally, histopathology at the end of the treatment revealed signs of inflammation.
Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available